Boston Scientific (BSX -0.5%) slips into the red today, despite saying it's received CE Mark...


Boston Scientific (BSX -0.5%) slips into the red today, despite saying it's received CE Mark approval for the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System, and is initiating its European market launch. The system is designed to provide physicians improved drug eluting stent performance for treating patients with coronary artery disease.

From other sites
Comments (2)
  • $CLU
    , contributor
    Comments (258) | Send Message
     
    Maybe the market doesn't like the name "Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System".
    It doesn't seem to roll off the tongue.
    12 Feb 2013, 03:00 PM Reply Like
  • gaidys
    , contributor
    Comment (1) | Send Message
     
    Tha's ok as long as the cholesterol rolls off the stent.
    13 Feb 2013, 02:41 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs